OncoCyte Corporation (OCX): Price and Financial Metrics

OncoCyte Corporation (OCX): $0.23

-0.01 (-5.42%)

POWR Rating

Component Grades














  • OCX scores best on the Sentiment dimension, with a Sentiment rank ahead of 87.17% of US stocks.
  • OCX's strongest trending metric is Momentum; it's been moving up over the last 49 days.
  • OCX's current lowest rank is in the Quality metric (where it is better than 0.93% of US stocks).

OCX Stock Summary

  • With a year-over-year growth in debt of -39.58%, ONCOCYTE CORP's debt growth rate surpasses only 7.32% of about US stocks.
  • The volatility of ONCOCYTE CORP's share price is greater than that of 90.26% US stocks with at least 200 days of trading history.
  • ONCOCYTE CORP's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -107.49%, greater than the shareholder yield of just 5.64% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to ONCOCYTE CORP, a group of peers worth examining would be BNGO, BLZE, NTRA, NCNO, and AMWL.
  • Visit OCX's SEC page to see the company's official filings. To visit the company's web site, go to www.oncocyte.com.

OCX Valuation Summary

  • In comparison to the median Healthcare stock, OCX's EV/EBIT ratio is 100% lower, now standing at 0.
  • OCX's EV/EBIT ratio has moved up 33.3 over the prior 88 months.

Below are key valuation metrics over time for OCX.

Stock Date P/S P/B P/E EV/EBIT
OCX 2023-03-17 3.9 0.4 -0.5 0.0
OCX 2023-03-16 4.4 0.5 -0.6 -0.1
OCX 2023-03-15 2.9 0.3 -0.4 0.1
OCX 2023-03-14 3.7 0.4 -0.5 0.0
OCX 2023-03-13 4.1 0.4 -0.5 -0.1
OCX 2023-03-10 5.0 0.5 -0.6 -0.2

OCX Growth Metrics

    Its 2 year price growth rate is now at -59.63%.
  • The 3 year net income to common stockholders growth rate now stands at -344.88%.
  • Its year over year cash and equivalents growth rate is now at -62.46%.
Over the past 33 months, OCX's revenue has gone up $8,097,000.

The table below shows OCX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 8.097 -42.985 -64.031
2022-06-30 8.064 -42.583 -68.276
2022-03-31 8.027 -39.373 -70.469
2021-12-31 7.727 -35.941 -64.097
2021-09-30 4.641 -35.026 -34.521
2021-06-30 4.212 -30.032 -27.504

OCX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OCX has a Quality Grade of F, ranking ahead of 0.09% of graded US stocks.
  • OCX's asset turnover comes in at 0.04 -- ranking 335th of 681 Pharmaceutical Products stocks.
  • ITCI, BHVN, and LFVN are the stocks whose asset turnover ratios are most correlated with OCX.

The table below shows OCX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.040 -0.136 -2.643
2021-03-31 0.030 -0.173 -1.674
2020-12-31 0.021 -0.525 -1.429
2020-09-30 0.013 -0.595 -1.555
2020-06-30 0.003 -2.384 -1.709
2020-03-31 0.000 -9.812 -2.256

OCX Price Target

For more insight on analysts targets of OCX, see our OCX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.67 Average Broker Recommendation 1.4 (Strong Buy)

OCX Stock Price Chart Interactive Chart >

Price chart for OCX

OCX Price/Volume Stats

Current price $0.23 52-week high $1.68
Prev. close $0.25 52-week low $0.20
Day low $0.22 Volume 655,300
Day high $0.27 Avg. volume 428,155
50-day MA $0.38 Dividend yield N/A
200-day MA $0.64 Market Cap 27.51M

OncoCyte Corporation (OCX) Company Bio

OncoCyte Corporation focuses on developing diagnostic tests for the detection of breast, bladder, and lung cancers. The company was founded in 2009 and is based in Alameda, California.

OCX Latest News Stream

Event/Time News Detail
Loading, please wait...

OCX Latest Social Stream

Loading social stream, please wait...

View Full OCX Social Stream

Latest OCX News From Around the Web

Below are the latest news stories about ONCOCYTE CORP that investors may wish to consider to help them evaluate OCX as an investment opportunity.

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

IRVINE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its fourth quarter and full year 2022 financial results on Wednesday, March 29, 2023. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone b

Yahoo | March 15, 2023

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Officer effective February 24, 2023. Since being named interim CEO in December, Riggs has successfully led the process of restructuring the Company by refocusing product strategy and reducing costs across the organization. Riggs also serves as President and joins the Company’s Board of Directors. “Since

Yahoo | March 2, 2023

Oncocyte Completes Razor Genomics Transaction

Company retains 30% stake while eliminating operating expense and future development obligations Represents next step in plan to focus product strategy IRVINE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has completed the sale of 70% of its ownership stake in wholly-owned subsidiary Razor Genomics to Dragon Scientific. The deal eliminates an estimated $8M of annual operating expense and $13M of future mile

Yahoo | February 22, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday!

William White on InvestorPlace | January 6, 2023

Oncocyte Announces Initiatives to Focus Corporate Strategy

IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocyte’s workforce to realign its team towards key products that address larger markets. Additionally, Oncocyte has entered into a Stock Purchase Agreement pursuant to which Oncocyte will transfer 70% of its ownership of Razor Genomics, Inc. to buyers who are leaders in the development of early stage lung cancer diagno

Yahoo | December 16, 2022

Read More 'OCX' Stories Here

OCX Price Returns

1-mo -42.50%
3-mo -39.47%
6-mo -71.25%
1-year -83.45%
3-year -88.56%
5-year -82.96%
YTD -28.33%
2022 -85.21%
2021 -9.21%
2020 6.22%
2019 63.04%
2018 -70.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9958 seconds.